First surgical cases in Hong Kong and Malaysia mark ReNerve’s Asia-Pacific commercial breakthrough
ReNerve Limited (ASX: RNV) has completed its first commercial surgical cases using the NervAlign® Nerve Cuff in both Hong Kong and Malaysia, converting regulatory approvals into operating theatre use across two key Asia-Pacific markets. The milestone brings ReNerve’s active commercial jurisdictions to seven, spanning the USA, New Zealand, Hong Kong, Thailand, Malaysia, Indonesia, and the Philippines. The announcement builds on record FY26 sales of $510,357, up 88% on the prior year, as the company’s international expansion layers on top of a growing US base.
Hong Kong: STC distributor moves quickly from stocking order to operating theatre
The Hong Kong cases follow a series of commercial and regulatory milestones announced earlier in 2026, including expanded product approval across Hong Kong, Macau, and the Greater Bay Area. ReNerve also appointed STC as its exclusive distributor under a three-year agreement, covering a combined addressable population of approximately 88 million people.
The exclusive Hong Kong distribution agreement with STC was signed ahead of first stocking orders, giving the distributor a regulatory and commercial runway to begin surgeon education and hospital in-servicing before cases commenced.
Initial stocking orders shipped in June 2026, and first commercial cases are now complete. STC, a Hong Kong-headquartered medical device distributor with established hospital and surgeon relationships across the region, has commenced surgeon education and product in-servicing at major hospitals, with further cases scheduled over the remainder of the year.
Malaysia: Market registration converts to first case at Thomson Hospital Kuala Lumpur
ReNerve received its Malaysia market registration for the NervAlign® Nerve Cuff in January 2026. The company’s first Malaysian surgical case was subsequently performed at Thomson Hospital in Kuala Lumpur, converting that regulatory approval into commercial use in a market of 35 million people.
Malaysia holds particular strategic significance within ReNerve’s regional plan. Several Malaysian hospital groups operate across multiple South-East Asian countries, using hospitals in Malaysia to provide services to patients across the region, positioning the market as a potential gateway for broader South-East Asian adoption rather than a standalone opportunity.
CEO Dr Julian Chick
“Completing our first cases in Hong Kong and Malaysia within months of securing approval and appointing distributors is exactly the kind of execution we set out to deliver. Regulatory approval is only the starting line – what matters is surgeons choosing to use NervAlign® in the operating theatre, and that is now happening in both markets.”
When big ASX news breaks, our subscribers know first
What is peripheral nerve injury repair and why does NervAlign® matter?
Peripheral nerve injury (PNI) refers to damage to the nerves outside the brain and spinal cord, which can result from trauma, surgery, or disease. The consequences for patients can include chronic pain, loss of sensation, and reduced physical function, significantly affecting quality of life.
A nerve cuff device wraps around a repaired nerve, protecting it and creating an optimal environment for healing. ReNerve’s NervAlign® Nerve Cuff is bioabsorbable, meaning it is naturally absorbed by the body within approximately six months of surgery. Clinical study data included in the announcement illustrates its impact: patients treated with NervAlign® saw post-surgical pain scores drop from 7.1 to 0.4, compared to a reduction from 7.1 to 3.3 for those treated with standard of care, a statistically significant difference.
The broader market context underlines the commercial opportunity. The global nerve repair biomaterials market was valued at US$1.6 billion in 2024 and is projected to reach US$6.2 billion by 2031, reflecting growing demand for improved surgical solutions in this field.
US momentum and FY26 results underpin the Asia-Pacific expansion story
The Asia-Pacific push is being built on top of a growing US business, not in place of it. ReNerve reported FY26 sales of $510,357, up 88% on FY25 ($272,000), with the June 2026 quarter delivering a record $211,000, representing 50% growth on the March 2026 quarter.
Sales momentum has carried into FY27, with the company noting even stronger sales in the current quarter. ReNerve indicated it will provide further detail in the next Appendix 4C quarterly report.
Key US milestones achieved during FY26 include:
- Distribution network expanded to 25 partners
- Purchasing approvals secured across the US Department of Defense and Veterans Affairs healthcare systems
- Empliq® human tissue product range launched and now making a meaningful contribution to revenue
- J4 Biologics appointed as a second manufacturing partner for Empliq® to support scalability and supply-chain resilience
CEO Dr Julian Chick
“Importantly, this regional expansion is being built on top of a US business that is growing strongly. With 25 distribution partners, access to the DoD and VA systems, and Empliq® now contributing alongside NervAlign®, we have multiple channels supporting our growth. FY26 was our strongest year yet and remain focused on executing our commercial strategy in FY27.”
The table below summarises ReNerve’s commercial footprint across its seven active jurisdictions.
| Jurisdiction | Product | Status | Key milestone | Period |
|---|---|---|---|---|
| USA | NervAlign® Nerve Cuff / Empliq® | Commercially active | 25 distribution partners; DoD and VA purchasing approvals; Empliq® contributing to revenue | FY26 (ongoing) |
| New Zealand | Not specified | Commercially active | Commercial use established | Not specified |
| Hong Kong | NervAlign® Nerve Cuff | Commercially active | First surgical cases completed; STC appointed exclusive distributor (3-year agreement); stocking orders shipped June 2026 | 2026 |
| Thailand | Not specified | Commercially active | Commercial use established | Not specified |
| Malaysia | NervAlign® Nerve Cuff | Commercially active | First surgical case completed at Thomson Hospital Kuala Lumpur; market registration received January 2026 | 2026 |
| Indonesia | NervAlign® Nerve Cuff | Marketing approval received; commercial entry being advanced | Commercial entry advancement in progress | Next steps |
| Philippines | NervAlign® Nerve Cuff | Marketing approval received; commercial entry being advanced | Commercial entry advancement in progress | Next steps |
What’s next: pipeline, preclinical data and three markets on deck
The announcement outlines several forward-looking milestones across ReNerve’s commercial and development programs:
- Commercial entry is being advanced into Indonesia, the Philippines, and India, all of which have received NervAlign® Nerve Cuff marketing approval
- The NervAlign® Nerve Guide Matrix is progressing through Stage 3 of its four-stage development program, with completion currently targeted by the end of calendar 2026
- The NervAlign® Nerve Conduit is advancing through commercial scale-up ahead of market launch
- Twelve-month preclinical study data on the NervAlign® Nerve Guide Matrix is expected to be released in the coming weeks
For readers interested in how the pipeline product sits alongside the commercial NervAlign range, our deep-dive into the NervAlign Nerve Guide Matrix development program covers the four-stage production process, the FDA submission pathway, and the clinical unmet need the product targets by eliminating secondary harvesting from autograft surgery.
With seven active commercial jurisdictions, a US distribution base expanding across both government and private healthcare channels, a clinically validated lead product, and a pipeline advancing toward additional product launches, ReNerve’s growth story operates across multiple layers simultaneously.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button at Big News Blast to get the next market-moving announcement the moment it drops.